Tyrosine Kinase Inhibitor
Tuspetinib for Acute Myeloid Leukemia
Recruiting1 awardPhase 1 & 2
Sacramento, California
This trial is testing a new drug, HM43239, for patients with relapsed or refractory acute myeloid leukemia (AML). The goal is to find the safe dose range and to see how well the drug works.
Anti-tumor antibiotic
BH-30236 for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Recruiting1 awardPhase 1
New York, New York
"This trial is studying a new drug for people with relapsed or refractory acute myelogenous leukemia or higher-risk myelodysplastic syndrome. The study has two phases: Phase 1
Chemotherapy
Ziftomenib Combinations for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Greenville, South Carolina
This trial will test the safety and effectiveness of a drug called ziftomenib when used together with standard treatments for patients with a type of blood cancer called acute myeloid leukemia that has come back
Popular Filters
Trials for Acute Myeloid Leukemia Patients
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
CC-91633 for Leukemia
Recruiting1 awardPhase 1
La Jolla, California
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
Recruiting1 award
Aurora, Colorado
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
Trials for Acute Promyelocytic Leukemia Patients
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
CC-91633 for Leukemia
Recruiting1 awardPhase 1
La Jolla, California
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
Recruiting1 award
Aurora, Colorado
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
Trials for CD19 Positive Patients
CAR T-cell Therapy
CD19 CAR-T Cells for Leukemia and Lymphoma
Recruiting3 awardsPhase 1
Houston, Texas
This trial is testing a new treatment for leukemia and lymphoma that uses a combination of two types of blood cells, T cells and antibodies. The hope is that this will be a more effective treatment with fewer side effects than current treatments.
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
CAR T-cell Therapy
CAR T-Cell Therapy for Leukemia and Lymphoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new cancer treatment combining two existing methods: T cells and antibodies. Researchers hope that the combination will be stronger than either method alone in fighting the cancer.
Phase 3 Trials
DNA Methyltransferase Inhibitor
DFP-10917 for Acute Myeloid Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing an experimental treatment called DFP-10917 against standard treatments for relapsed or refractory acute myeloid leukemia (AML). Patients in the experimental arm will receive DFP-10917 by continuous intravenous infusion for 14 days, followed by a 14-day resting period, for up to 6 cycles. Patients in the control arm will receive standard treatments, which may include non-intensive reinduction or intensive reinduction, depending on the patient's prior induction treatment.
Chemotherapy
Ivosidenib + Azacitidine for Acute Myeloid Leukemia
Recruiting1 awardPhase 3
Winnipeg, Manitoba
This trial is testing a new oral drug, ivosidenib, combined with an injectable drug, azacitidine. It targets adults with a specific type of untreated leukemia who can't undergo intensive treatments. Ivosidenib blocks a faulty enzyme in cancer cells, and azacitidine stops these cells from growing.
Radioimmunotherapy
Iomab-B + HCT for Acute Myeloid Leukemia
Recruiting2 awardsPhase 3
Gilbert, Arizona
This trial is testing a new treatment for AML patients who have relapsed or are unresponsive to other treatments. The new treatment consists of a reduced intensity conditioning regimen in conjunction with Iomab-B and allogeneic hematopoietic stem cell transplant.
Chemotherapy
New Cancer Treatment for Non-Hodgkin's Lymphoma
Recruiting1 awardPhase 2 & 3
San Diego, California
This trial is testing a new cancer treatment for children with B-cell NHL. The new treatment is based on the successful LMB-96 regimen. The trial features prospective biologic and late effect studies.
Trials With No Placebo
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
CC-91633 for Leukemia
Recruiting1 awardPhase 1
La Jolla, California
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
Recruiting1 award
Aurora, Colorado
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.